Recipharm Invests $1.3 Million in API Facility
Recipharm, a contract development and manufacturing organization based in Jordbro, Sweden, has invested more than EUR1.2 million ($1.3 million) to enhance its small-scale GMP active pharmaceutical ingredient development and manufacturing capabilities in Paderno Dugnano, Italy, by opening a new GMP kilo laboratory.
As part of the investment, the facility’s existing chemical development laboratories have been upgraded with the addition of technologies and a dedicated unit for analytical development and method analysis activities. Analytical technologies under evaluation include high performance liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry, nuclear magnetic resonance spectroscopy, and ultra-performance liquid chromatography method scouting solutions.
To support the new capabilities, Recipharm plans to double its research and development team in Paderno Dugnano over the next three years.
This is the latest in a series of investments that Recipharm has recently made. In February 2016, the company announced an EUR 40 million ($44.2 million) investment over the next three years to provide solutions for the serialization processes. The investment is in line with the European Union’s (EU) Falsified Medicines Directive Safety Features Delegated Regulation, which requires that serialization of licensed drug products in the EU from early 2019.
In July 2016, Recipharm announced an EUR 18 million ($19.9 million) investment to expand its blow/fill/ seal capacity at its site in Kaysersberg, France. The expansion will add a new blow/fill/seal high-speed filling and packaging line, bringing the total number of lines from seven to eight.
In August 2016, the company announced it had invested EUR 3.7 million ($4.1 million) to expand its lyophilization capacity at its site in Masate, Italy. This investment is in addition to an ongoing EUR 32 million ($35 million) investment at the company’s site in Wasserburg, Germany to increase capacity.
Following that, in October 2016, it announced an investment of SEK 5 million ($0.55 million) in a new GLP-compliant bioanalysis laboratory at its development facility in Uppsala, Sweden. The investment will see the opening of a 500-square-meter purpose-built facility in November 2016. From its new laboratory, Recipharm will increase its capacity, with the capability to process more than 10,000 plasma samples per week.